So I'm going to hand it over now to Dr. Rendell.

Thank you, Dr. Schneider.

So now we'll talk about the prioritization of shingles vaccination and some efficacy, safety, and serious completion information.

So let's apply the vaccination to a real-world scenario.

You have a visit with a 55-year-old patient who has diabetes and has not yet received the shingles vaccine.

What would you do next? Would you wait until the patient develops shingles? Would you offer the recombinant zoster vaccine now? Would you delay vaccination until age 65, or would you only vaccinate if symptoms develop? So the correct answer is to offer the recombinant zoster vaccine now.

We don't wait for shingles to occur.

So maybe to Dr. Rendell, how does the growing recognition of shingles as a multi-system condition, including cardiovascular disease or cardiovascular risk and functional decline, influence your clinical decision-making and patient discussions?